MBL2 and cancer: To confirm the impact of altered ECM1, MBL2, BTD and RAB5C expression in existing clinical patient studies, we analysed four biomarker‐altered and non‐altered groups with a survival of 1084 patients in the pan‐cancer atlas (Figure 7C) and 2509 patients in the METABRIC data (Figure 7D).